Document Detail


Maternal drug use and its effect on neonates: a population-based study in washington state.
MedLine Citation:
PMID:  22525903     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
OBJECTIVE: : To estimate the effect of maternal illicit and prescription drug use on neonates in Washington State between 2000 and 2008.
METHODS: : We used state-linked birth certificate and hospital discharge (mother and neonate) data to calculate prenatal drug exposure and neonatal abstinence syndrome rates, and compared state neonatal abstinence syndrome rates with national-level data from the Nationwide Inpatient Sample. We identified the drugs of exposure, examined predictors of drug exposure and neonatal abstinence syndrome, and assessed perinatal outcomes among drug-exposed and neonatal abstinence syndrome-diagnosed neonates compared with unexposed neonates.
RESULTS: : Drug exposure and neonatal abstinence syndrome rates increased significantly between 2000 and 2008, neonatal abstinence syndrome rates being consistently higher than national figures (3.3 compared with 2.8 per 1,000 births in 2008; P<.05). The proportion of neonatal abstinence syndrome-diagnosed neonates exposed prenatally to opioids increased from 26.4% in 2000 to 41.7% in 2008 (P<.05). Compared with unexposed neonates, drug-exposed and neonatal abstinence syndrome-diagnosed neonates had a lower mean birth weight, longer birth hospitalization, were more likely to be born preterm, experience feeding problems, and have respiratory conditions (all P<.001).
CONCLUSION: : Maternal use of illicit and prescription drugs was associated with considerable neonatal morbidity and significantly higher rates of drug exposure and neonatal abstinence syndrome in recent years. Data suggest that opioid analgesics contributed to the increase in prenatal drug exposure and neonatal abstinence syndrome in Washington State. In accordance with current guidelines, our findings emphasize the need for clinicians to screen pregnant women for illicit and prescription drug use and minimize use of opioid analgesics during pregnancy.
LEVEL OF EVIDENCE: : II.
Authors:
Andreea A Creanga; Jennifer C Sabel; Jean Y Ko; Cathy R Wasserman; Carrie K Shapiro-Mendoza; Polly Taylor; Wanda Barfield; Laurie Cawthon; Leonard J Paulozzi
Related Documents :
22401643 - Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clin...
3022583 - Angiotensin converting enzyme inhibitors in congestive heart failure. overview in compa...
3545523 - Aspects of cytotoxic drug penetration, with particular reference to anthracyclines.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Obstetrics and gynecology     Volume:  119     ISSN:  1873-233X     ISO Abbreviation:  Obstet Gynecol     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0401101     Medline TA:  Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  924-33     Citation Subset:  AIM; IM    
Affiliation:
From the Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, the Epidemic Intelligence Service, Office of Workforce and Career Development, and the Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia; and the Washington State Departments of Health and Social and Health Services, Research and Data Analysis, Olympia, Washington.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of Antenatal Corticosteroids on Fetal Growth and Gestational Age at Birth.
Next Document:  Mood symptoms after natural menopause and hysterectomy with and without bilateral oophorectomy among...